Association Between CYP450 Polymorphisms and Treatment Outcomes of Escitalopram and Venlafaxine in Patients with Post Stroke Depression
Yanyan Wang, Wenzhe Sun, Chensheng Pan, Zhou Zhu, Guo Li, Xin Zhao, Suiqiang Zhu · 2026
Read Association Between CYP450 Polymorphisms and Treatment Outcomes of Escitalopram and Venlafaxine in Patients with Post Stroke Depression by Yanyan Wang, Wenzhe Sun, Chensheng Pan, Zhou Zhu, Guo Li, Xin Zhao, Suiqiang Zhu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13546662.txt.
Description
Yanyan Wang and co-authors test whether genes for drug breakdown predict who responds to two antidepressants after a stroke, in a 2026 study. Depression after stroke is common, and patients vary widely in how well escitalopram or venlafaxine works for them. The team enrolled 313 patients at one center, sorted them by their CYP2C19 or CYP2D6 gene types into fast and slow metabolizers, and tracked depression scores over eight weeks.
Among the escitalopram patients, slow and fast groups improved by nearly the same amount, with similar response and remission rates. The venlafaxine arm turned out too lopsided in gene types to judge. Gene-guided picking of these two drugs gains little support here.
Catalog record
| CREATOR | Yanyan Wang, Wenzhe Sun, Chensheng Pan, Zhou Zhu, Guo Li, Xin Zhao, Suiqiang Zhu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |